Primary Hepatic Leiomyosarcoma in Adults: Analysis of Prognostic Factors

被引:21
作者
Chi, Ming [1 ]
Dudek, Arkadiusz Z. [2 ]
Wind, Kenneth P. [3 ]
机构
[1] Univ Illinois, St Joseph Hosp, Dept Med, Chicago, IL 60657 USA
[2] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA
[3] Univ Illinois, St Joseph Hosp, Dept Pathol, Chicago, IL 60657 USA
来源
ONKOLOGIE | 2012年 / 35卷 / 04期
关键词
Liver neoplasms; Leiomyosarcoma; Adult; Prognostic factors; GEMCITABINE PLUS DOCETAXEL; LIVER-TRANSPLANTATION; MANAGEMENT; FEATURES; SARCOMAS; TUMORS;
D O I
10.1159/000337416
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Primary hepatic leiomyosarcoma (LMS) is a rare malignancy of the liver in adults, with variable overall survival (OS). The main purpose of this study was to identify prognostic factors of improved survival. Relevant data were abstracted from MEDLINE, EMBASE, and Academic Search Premiere (ASP), and from the medical records of a patient treated at our institution. Multivariate analysis was conducted by generating Cox proportional hazard ratios. We identified 109 patients with primary hepatic LMS; 95 were included for basic description, and 84 for OS analysis. Median age was 58 years (range 19-86 years), 45.0% of the patients were female, and 21.1% were AJCC stage IV. The primary treatment for all 95 patients was as follows: 61.1% had surgery, 13.7% had chemotherapy, 5.3% had liver transplantation, 2.1% received radiotherapy, and 14.7% were managed conservatively. Median OS was 19 months (range 0-181 months) with 1-, 2-, and 5-year survival rates of 61.2, 41.1, and 14.5%, respectively. In a multivariate analysis, smaller size of the largest hepatic lesion (p = 0.038) and negative resection margin (p = 0.0004) were associated with improved survival. Complete surgical resection with clear margin is necessary to improve survival of patients with primary hepatic LMS.
引用
收藏
页码:210 / 214
页数:5
相关论文
共 30 条
  • [1] Unusual evolution of an Epstein-Barr virus-associated leiomyosarcoma occurring after liver transplantation
    Brichard, B
    Smets, F
    Sokal, E
    Clapuyt, P
    Vermylen, C
    Cornu, G
    Rahier, J
    Otte, JB
    [J]. PEDIATRIC TRANSPLANTATION, 2001, 5 (05) : 365 - 369
  • [2] El Mesbahi O, 2006, ONCOLOGIE, V8, P927
  • [3] Primary liver leiomyosarcoma: CT appearance
    Ferrozzi, F
    Bova, D
    Zangrandi, A
    Garlaschi, G
    [J]. ABDOMINAL IMAGING, 1996, 21 (02): : 157 - 160
  • [4] Gemcitabine/docetaxel - Welcome to a new standard
    Fleming, Gini
    [J]. GYNECOLOGIC ONCOLOGY, 2008, 109 (03) : 313 - 315
  • [5] PRIMARY LEIOMYOSARCOMA OF LIVER
    FONG, JA
    RUEBNER, BH
    [J]. HUMAN PATHOLOGY, 1974, 5 (01) : 115 - 119
  • [6] Hensley M, 2010, J CLIN ONCOL S, V28, p15s
  • [7] Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine lelomyosarcoma: A Gynecologic Oncology Group phase II trial
    Hensley, Martee L.
    Blessing, John A.
    Mannel, Robert
    Rose, Peter G.
    [J]. GYNECOLOGIC ONCOLOGY, 2008, 109 (03) : 329 - 334
  • [8] Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study
    Hensley, Martee L.
    Ishill, Nicole
    Soslow, Robert
    Larkin, Joseph
    Abu-Rustum, Nadeem
    Sabbatini, Paul
    Konner, Jason
    Tew, William
    Spriggs, David
    Aghajanian, Carol A.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 112 (03) : 563 - 567
  • [9] Liver transplantation for primary or metastatic sarcoma to the liver
    Husted, TL
    Neff, G
    Thomas, MJ
    Gross, TG
    Woodle, ES
    Buell, JF
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (02) : 392 - 397
  • [10] Ishii H, 1991, Nihon Shokakibyo Gakkai Zasshi, V88, P1256